Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2023 Earnings Call October 26, 2023 4:30 PM ET

Company Participants

Matt Steinberg - Investor Relations

Scott Davis - Chief Executive Officer

Jason Jones - Chief Operating Officer

Jerome Wong - Chief Financial Officer

Conference Call Participants

Sean Lee - H.C. Wainwright

Operator

Greetings, and welcome to the Ekso Bionics Quarter Three 2023 Financial Results Call.

At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions). As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Matt Steinberg of FinPartners. Please go ahead.

Matt Steinberg

Thank you, operator. And thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; Jason Jones, Chief Operating Officer; and Jerome Wong, Chief Financial Officer.

Earlier today, Ekso Bionics released financial results for the third quarter of 2023. A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that management will make statements during this call that include forward looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements made during this call that are not statements of historical facts should be deemed to be forward looking statements. All forward looking statements, including statements regarding our business strategy, future financial or operational expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions.

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission.

Ekso disclaims any intention or obligation, except as required by law, to update or revise any financial or operational projections. Regulatory outlook or other forward-looking statements, whether because of new information, future events or otherwise, which speak only as of today, October 26, 2023.

I'll now turn the call over to Ekso Bionics' CEO, Scott Davis.

Scott Davis

Thank you, Matt, and thank you to everyone for joining us today. I'm pleased to announce that we achieved another strong quarter of sales for EksoNR and Indego devices. That propelled us to grow our quarterly revenues by a significant 38% year-over-year. In addition, we've established the groundwork our EksoWorks segment, resulting in a record quarterly number of EVO unit sales.